Tumor-infiltrating T-cells: Important players in clinical outcome of advanced melanoma patients

OncoImmunology

Volumn 3, Issue 9, 2014, Pages 1-3

  Tjin, Esther P M ^a   Luiten, Rosalie M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Clinical outcome; Immune escape mechanisms; Immunotherapy; Melanoma; Tumor infiltrating T cells

Indexed keywords

TUMOR CELL VACCINE;

ADOPTIVE TRANSFER; ADVANCED CANCER; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; HUMAN; IMMUNE ESCAPE; IMMUNE RESPONSE; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR INFILTRATING T LYMPHOCYTE;

EID: 84921627194     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.954862     Document Type: Article

References (10)

1. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood- 2008-12-195792
2. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995; 378:736-9; PMID:7501023; http://dx.doi.org/ 10.1038/378736a0
3. Zubieta M R, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 2006; 168:1666-75; PMID:16651632
4. Gabrilovich D I, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74.
5. Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA, Haanen JB, Melief CJ, et al. Immuneescape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. Cancer Immunol Res 2014; 2:538-46; PMID:24894091; http://dx.doi.org/10.1158/2326- 6066.CIR-13-0097
6. Ladanyi A, Somlai B, Gilde K, Fejos Z, Gaudi I, Timar J. T-cell activation marker expression on tumorinfiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 10:521-30; PMID:14760073
7. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007; 25:869-75; http://dx.doi. org/10.1200/JCO.2006.08.9755
8. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013; 19:4792- 800; PMID:23690483; http://dx.doi.org/10.1158/ 1078-0432.CCR-13-0380
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54.